|
Video: What is a Stock Split?
|
|
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Co.'s pipeline consists of four product candidates, two of which it is pursuing for its development, etavopivat for the treatment of sickle cell disease (SCD), and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Co.'s main product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy initially being studied for the treatment of SCD. According to our FMTX stock split history records, FMTX has had 0 splits. | |
|
FMTX (FMTX) has 0 splits in our FMTX stock split history database.
Looking at the FMTX stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into FMTX shares, starting with a $10,000 purchase of FMTX, presented on a split-history-adjusted basis factoring in the complete FMTX stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/22/2020 |
|
End date: |
10/14/2022 |
|
Start price/share: |
$39.95 |
|
End price/share: |
$20.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-49.91% |
|
Average Annual Total Return: |
-25.84% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,009.45 |
|
Years: |
2.31 |
|
|
|
|
|